MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway

Retraction in: /10.3892/ijo.2022.5420

  • Authors:
    • Yilin Liu
    • Yuqiang Wang
    • Hao Yang
    • Liang Zhao
    • Ruipeng Song
    • Hongyu Tan
    • Limin Wang
  • View Affiliations

  • Published online on: February 28, 2019     https://doi.org/10.3892/ijo.2019.4735
  • Pages: 1809-1820
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Several microRNAs (miRNAs or miRs) that regulate a variety of cancer‑related events are dysregulated in osteosarcoma (OS). An exploration of the specific roles of miRNAs in OS is crucial for the identification of suitable therapeutic targets. Previous studies have shown that miR‑873 plays tumor suppressive or oncogenic roles in different types of cancer. However, whether miR‑873 is implicated in OS carcinogenesis and cancer progression remains poorly understood. In the present study, we demonstrated that the miR‑873 levels were decreased in OS tissues and cell lines. The decreased expression of miR‑873 was related to tumor size, clinical stage and distant metastasis in patients with OS. The introduction of miR‑873 significantly inhibited tumor cell proliferation, migration and invasion in vitro, promoted apoptosis in vitro and restricted tumor growth in vivo. Furthermore, homeobox A9 (HOXA9) was validated as a direct target gene of miR‑873 in OS cells. HOXA9 was markedly expressed in OS tissues, and its upregulation inversely correlated with the miR‑873 levels. Moreover, HOXA9 silencing produced similar effects as observed with miR‑873 overexpression in OS cells. Consistently, the exogenous expression of HOXA9 partially reversed the suppression of the aggressive phenotype induced by miR‑873 overexpression in OS cells. Notably, miR‑873 was able to deactivate the Wnt/β‑catenin pathway in OS cells by regulating HOXA9, both in vitro and in vivo. On the whole, the present study demonstrates that miR‑873 suppresses the development of OS by directly targeting HOXA9 and inhibiting the Wnt/β‑catenin pathway, and suggests that miR‑873 may prove to be useful as a diagnostic biomarker of OS, as well as in the development of novel therapies.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 54 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Wang Y, Yang H, Zhao L, Song R, Tan H and Wang L: MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway Retraction in /10.3892/ijo.2022.5420. Int J Oncol 54: 1809-1820, 2019.
APA
Liu, Y., Wang, Y., Yang, H., Zhao, L., Song, R., Tan, H., & Wang, L. (2019). MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway Retraction in /10.3892/ijo.2022.5420. International Journal of Oncology, 54, 1809-1820. https://doi.org/10.3892/ijo.2019.4735
MLA
Liu, Y., Wang, Y., Yang, H., Zhao, L., Song, R., Tan, H., Wang, L."MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway Retraction in /10.3892/ijo.2022.5420". International Journal of Oncology 54.5 (2019): 1809-1820.
Chicago
Liu, Y., Wang, Y., Yang, H., Zhao, L., Song, R., Tan, H., Wang, L."MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway Retraction in /10.3892/ijo.2022.5420". International Journal of Oncology 54, no. 5 (2019): 1809-1820. https://doi.org/10.3892/ijo.2019.4735